Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
Julie C. Friedland(Synta Pharmaceuticals (United States)), David A. Proia(Synta Pharmaceuticals (United States))
Cited by 58
Related Papers
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
|Investigational New Drugs|2012|79
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
|Investigational New Drugs|2014|73
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
|International Journal of Oncology|2012|60